Taking the drug «BX-204» to Phase III: €180 million over three years
Pharma
The result is a statistical mirage — and the benchmark is about to change.
In the scenario Avoided a €180M trial potentially aimed at the wrong target.
The protagonist & the context
The Chief Medical Officer of clinical development, with a €180 million program already in start-up and an executive committee demanding to move before the competitor reaches the finish line.
A mid-sized pharmaceutical company with a single molecule in advanced development. BX-204 is a candidate for a niche oncology indication — few patients, high unmet need, high expected price. The Phase III budget is the company's largest bet in the past decade.
Background
The Phase II signal arrived unevenly: two of the twelve enrolment centers contributed more than half of the total response, and the biomarker-positive subgroup showed an effect almost double that of the general population. In oncology literature, this pattern — response driven by a few expert centers or a narrow subgroup — recurs regularly in Phase III failures: the effect does not replicate across the more heterogeneous population of large trials. At the same time, the main competitor has released preliminary data on an agent with a different mechanism of action that could redefine the standard-of-care protocol within eighteen to twenty-four months. If the reference comparator changes, the current trial design loses regulatory validity.
The dilemma
Internal pressure is strong: Phase II data are positive, the competitive window is narrow, and every month of waiting burns resources and gives ground to the competitor. But the red team points to a detail management prefers not to isolate: strip out the two best centers and the biomarker cohort, and the residual effect is modest — probably insufficient for approval. Starting now means committing €180 million to a design that may not replicate, chasing a comparator that could become obsolete before the final readout. Waiting — or redesigning — costs time, but avoids running toward a moving target.
Exhibits
Estimated relative response in the total Phase II population vs the biomarker-positive subgroup — the gap signals a non-replication risk (illustrative data).
Share of total response attributable to each enrolment center — the two expert centers account for over half the overall signal (illustrative data).
The contradictor's analysis
- The effect seen in Phase II is real and will repeat at large scale.
- The indicator measured now truly predicts patient benefit.
- The reference drug we compare against will remain today's.
The result could be a statistical mirage. Much of the signal comes from a single patient subgroup and from two centers especially good at enrolling: on the true average, the effect is modest. And meanwhile a competitor is about to change the standard of care — the yardstick. You risk a €180 million trial aimed at a target that will soon no longer exist.
- Removing the two best centers, does the effect remain?
- In independent studies, does that indicator really predict the clinical outcome?
- How likely is the standard of care to change within 24 months?
- What is the real effect, once center and subgroup distortions are removed?
- If the standard of care changes, does the trial hold or must it be redone?
Provenance: Phase II data (by center and subgroup) · literature on the indicator · competitor intelligence · red-team base.
Resolution & consequences
Methodological note
Composite teaching case. Figures and details are illustrative; it is not a client outcome or a performance claim. Built, in the method of the Harvard Business Review, from recurring decision patterns in the sector, merged and anonymized to protect confidentiality. The «provenance» notes describe the type of evidence the engine cites with traceability in production. No Δ-CSI score is shown: composite cases have no frozen, reproducible scorecard.